Funding for the Cancer Research UK Manchester Institute

The total funding of the CRUK Manchester Institute for 2019 was £29.6m. The major source of this funding was awarded by Cancer Research UK (CRUK) via a core grant of £13.6m plus additional strategic funding of £6.3m. This funding enables the various scientific groups and service units within the Institute to carry out their research.   

Pie chart showing funding for 2019
 

The infrastructure of the CRUK Manchester Institute is funded by HEFCE generated income at a cost of £2.1m.  

The balance of the Institute’s funding is received from a number of additional sources.  The research carried out through these additional projects enhances and supports the research undertaken by the core funding.

These sources are as follows:

  • Amgen
  • Angle Inc
  • Astex Pharmaceuticals
  • AstraZeneca
  • Bioven
  • Bloodwise
  • Carrick Therapeutics
  • CellCentric
  • Christie Hospital NHS Foundation Trust
  • Clearbridge Biomedicals
  • CRT Pioneer Fund
  • David & Ruth Lewis Trust
  • Euclises Pharmaceuticals Inc
  • European Commission
  • European Organisation for Cancer Research and Treatment of Cancer
  • European Research Council
  • Fondation ARC pour la Recherche sur le Cancer
  • GlaxoSmithKline
  • Harry J Lloyd Charitable Trust
  • John Swallow Fellowship
  • Kay Kendal Leukaemia Fund
  • Leo Pharma Foundation
  • Menarini Biomarkers Singapore
  • Merck
  • Moulton Charitable Trust
  • National Institute of Health Research
  • Ono Pharmaceuticals
  • Pancreatic Cancer Research Fund
  • Pickering Leukaemia Research
  • Prostate Cancer UK
  • Rosetrees Trust
  • Taiho Oncology Inc
  • The US Department of Health and Human Services
  • Wellcome Trust
  • Worldwide Cancer Research

We are immensely grateful to all our sponsors.